Antipsychotic-induced hyperprolactinemia
- PMID: 19113797
- DOI: 10.1592/phco.29.1.64
Antipsychotic-induced hyperprolactinemia
Abstract
Use of antipsychotic agents has been associated with hyperprolactinemia, or elevated prolactin levels; this hormonal abnormality can interfere with the functioning of reproductive, endocrine, and metabolic systems. As antipsychotic agents are increasingly used for both United States Food and Drug Administration-approved and nonapproved indications, many individuals are at risk for developing antipsychotic-induced hyperprolactinemia. First-generation antipsychotics pose the greatest risk of causing this adverse effect; however, second-generation antipsychotics, particularly risperidone and paliperidone, also often increase prolactin secretion. Hyperprolactinemia has short- and long-term consequences that can seriously affect quality of life: menstrual disturbances, galactorrhea, sexual dysfunction, gynecomastia, infertility, decreased bone mineral density, and breast cancer. Although many of these are definitively connected to elevated prolactin levels, some, such as breast cancer, require further study. Both clinicians and patients should be aware of hyperprolactinemia-associated effects. To prevent or alleviate the condition, tailoring an antipsychotic drug regimen to each individual patient is essential. In addition, the risk of hyperprolactinemia can be minimized by using the lowest effective dose of the antipsychotic agent. If the effects of prolactin are evident, the drug can be changed to another agent that is less likely to affect prolactin levels; alternatively, a dopamine agonist may be added, although this may compromise antipsychotic efficacy. Additional research is needed to clarify the appropriate level of monitoring, the long-term effects, and the optimal treatment of antipsychotic-induced hyperprolactinemia.
Similar articles
-
[Antipsychotic-drug-induced hyperprolactinemia: physiopathology, clinical features and guidance].Encephale. 2014 Feb;40(1):86-94. doi: 10.1016/j.encep.2012.03.002. Epub 2013 Aug 5. Encephale. 2014. PMID: 23928066 Review. French.
-
Clinical implications of antipsychotic-induced hyperprolactinemia in patients with schizophrenia spectrum or bipolar spectrum disorders: recent developments and current perspectives.J Clin Psychopharmacol. 2007 Dec;27(6):639-61. doi: 10.1097/jcp.0b013e31815ac4e5. J Clin Psychopharmacol. 2007. PMID: 18004132 Review.
-
Hyperprolactinaemia and antipsychotic therapy in schizophrenia.Curr Med Res Opin. 2004;20(2):189-97. doi: 10.1185/030079903125002865. Curr Med Res Opin. 2004. PMID: 15006013 Review.
-
Antipsychotic-induced hyperprolactinemia and sexual dysfunction.Psychopharmacol Bull. 2002 Winter;36(1):143-64. Psychopharmacol Bull. 2002. PMID: 12397853 Review.
-
Prolactin elevation with antipsychotic medications: mechanisms of action and clinical consequences.J Clin Psychiatry. 2002;63 Suppl 4:56-62. J Clin Psychiatry. 2002. PMID: 11913677 Review.
Cited by
-
Association between prolactin increasing antipsychotic use and the risk of breast cancer: a retrospective observational cohort study in a United States Medicaid population.Front Oncol. 2024 Mar 25;14:1356640. doi: 10.3389/fonc.2024.1356640. eCollection 2024. Front Oncol. 2024. PMID: 38595824 Free PMC article.
-
Population Pharmacodynamic Models of Risperidone on PANSS Total Scores and Prolactin Levels in Schizophrenia.Pharmaceuticals (Basel). 2024 Jan 23;17(2):148. doi: 10.3390/ph17020148. Pharmaceuticals (Basel). 2024. PMID: 38399363 Free PMC article.
-
The effect of antipsychotic medication and the associated hyperprolactinemia as a risk factor for periodontal diseases in schizophrenic patients: a cohort retrospective study.BMC Oral Health. 2023 Oct 24;23(1):786. doi: 10.1186/s12903-023-03404-1. BMC Oral Health. 2023. PMID: 37875841 Free PMC article.
-
Gender differences in clinical and biochemical parameters among patients hospitalized for schizophrenia: towards precision medicine.Eur Arch Psychiatry Clin Neurosci. 2023 Jul 12. doi: 10.1007/s00406-023-01644-4. Online ahead of print. Eur Arch Psychiatry Clin Neurosci. 2023. PMID: 37436457
-
Place of care and costs associated with acute episodes and remission in schizophrenia.J Manag Care Spec Pharm. 2023 May;29(5):499-508. doi: 10.18553/jmcp.2023.29.5.499. J Manag Care Spec Pharm. 2023. PMID: 37121252 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials